Reaction
Spleen Disorder reporting signals
As of the last recalculation, Spleen Disorder appears in 1,678 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is RUXOLITINIB (PRR 37.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ruxolitinib | 194 | 37.8 | 37.9 |
| Hydroxyurea | 39 | 23.4 | 23.4 |
| Deferasirox | 29 | 13.8 | 13.8 |
| Cladribine | 10 | 13.0 | 13.0 |
| Hydrocortisone Sodium Succinate | 9 | 11.9 | 11.9 |
| Bosutinib | 8 | 11.1 | 11.1 |
| Romiplostim | 13 | 10.8 | 10.8 |
| Lanreotide Acetate | 6 | 9.5 | 9.5 |
| Methimazole | 6 | 9.5 | 9.5 |
| Avapritinib | 7 | 7.2 | 7.2 |
| Dolutegravir Sodium | 5 | 6.9 | 6.9 |
| Nilotinib | 16 | 6.8 | 6.8 |
| Dabrafenib | 11 | 6.5 | 6.5 |
| Bendamustine Hcl | 8 | 6.4 | 6.4 |
| Acalabrutinib | 6 | 6.2 | 6.2 |
| Trametinib | 10 | 5.2 | 5.2 |
| Ibrutinib | 33 | 5.1 | 5.2 |
| Polatuzumab Vedotin | 4 | 5.1 | 5.1 |
| Eltrombopag Olamine | 9 | 4.9 | 4.9 |
| Rucaparib | 3 | 4.2 | 4.2 |
| Venetoclax | 19 | 3.9 | 3.9 |
| Voxelotor | 6 | 3.3 | 3.3 |